There are two ways to make a bioresorbable, drug-eluting scaffold, according to Amaranth Medical CEO Kamal Ramzipoor.
“The Amaranth way, or the conventional way, which our competition is using,” he told Drug Delivery Business News. “What we’ve seen throughout the years is the conventional method has some very significant limitations. And that’s what has manifested itself into, unfortunately, what’s going on.”
Bioresorbable scaffolds have been plagued by safety concerns, highlighted recently by Abbott‘s (NYSE:ABT) Absorb device, which it pulled from the market in September due to low sales. In October, a European task force recommended that physicians favor current-generation drug-eluting stents over bioresorbable scaffolds, citing concerns about the increased risk of myocardial infarction and scaffold thrombosis linked with bioresorbable devices.
Amaranth’s chief executive said he knows that his company’s devices need to live up to the efficacy expectations set by drug-eluting stents.